vs
Side-by-side financial comparison of Legacy Housing Corp (LEGH) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Legacy Housing Corp is the larger business by last-quarter revenue ($25.5M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 32.2%, a 33.6% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -30.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -9.1%).
Legacy Housing Corp is a prominent U.S.-based manufacturer of affordable manufactured homes, tiny homes, and accessory dwelling units. It mainly caters to low- and middle-income consumers across North America, providing customizable residential solutions, supporting construction materials, and after-sales services for individual and community development clients.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
LEGH vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.5M | $18.6M |
| Net Profit | $8.2M | $12.3M |
| Gross Margin | 26.4% | — |
| Operating Margin | 40.4% | 56.3% |
| Net Margin | 32.2% | 65.7% |
| Revenue YoY | -30.6% | 1808.5% |
| Net Profit YoY | -43.5% | 376.5% |
| EPS (diluted) | $0.38 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.5M | $18.6M | ||
| Q3 25 | $28.8M | $334.0K | ||
| Q2 25 | $38.4M | $1.4M | ||
| Q1 25 | $24.3M | $257.0K | ||
| Q4 24 | $36.7M | $977.0K | ||
| Q3 24 | $30.2M | $660.0K | ||
| Q2 24 | $31.7M | $736.0K | ||
| Q1 24 | $30.8M | $1.4M |
| Q4 25 | $8.2M | $12.3M | ||
| Q3 25 | $8.6M | $-8.6M | ||
| Q2 25 | $14.7M | $-6.9M | ||
| Q1 25 | $10.3M | $-5.4M | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | $15.8M | $-2.8M | ||
| Q2 24 | $16.2M | $-14.5M | ||
| Q1 24 | $15.1M | $411.0K |
| Q4 25 | 26.4% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 32.4% | — | ||
| Q1 25 | 29.2% | — | ||
| Q4 24 | 27.3% | — | ||
| Q3 24 | 29.2% | — | ||
| Q2 24 | 31.9% | — | ||
| Q1 24 | 33.6% | — |
| Q4 25 | 40.4% | 56.3% | ||
| Q3 25 | 33.7% | -2516.5% | ||
| Q2 25 | 43.8% | -701.0% | ||
| Q1 25 | 47.7% | -3350.2% | ||
| Q4 24 | 42.3% | — | ||
| Q3 24 | 50.8% | -1563.6% | ||
| Q2 24 | 50.6% | -1255.0% | ||
| Q1 24 | 54.3% | -692.5% |
| Q4 25 | 32.2% | 65.7% | ||
| Q3 25 | 30.0% | -2572.2% | ||
| Q2 25 | 38.3% | -504.8% | ||
| Q1 25 | 42.3% | -2097.7% | ||
| Q4 24 | 39.5% | — | ||
| Q3 24 | 52.4% | -425.5% | ||
| Q2 24 | 51.1% | -1964.4% | ||
| Q1 24 | 49.1% | 29.9% |
| Q4 25 | $0.38 | $0.25 | ||
| Q3 25 | $0.35 | $-0.17 | ||
| Q2 25 | $0.60 | $-0.14 | ||
| Q1 25 | $0.41 | $-0.11 | ||
| Q4 24 | $0.59 | — | ||
| Q3 24 | $0.64 | $-0.06 | ||
| Q2 24 | $0.65 | $-0.30 | ||
| Q1 24 | $0.60 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $528.6M | $49.4M |
| Total Assets | $580.3M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $40.0M | ||
| Q3 25 | $13.6M | $37.9M | ||
| Q2 25 | $2.6M | $44.8M | ||
| Q1 25 | $3.4M | $40.6M | ||
| Q4 24 | $1.1M | $59.3M | ||
| Q3 24 | $570.0K | $68.8M | ||
| Q2 24 | $60.0K | $73.0M | ||
| Q1 24 | $621.0K | $80.2M |
| Q4 25 | $528.6M | $49.4M | ||
| Q3 25 | $521.6M | $36.4M | ||
| Q2 25 | $512.8M | $44.5M | ||
| Q1 25 | $503.7M | $50.5M | ||
| Q4 24 | $494.0M | $55.1M | ||
| Q3 24 | $479.3M | $58.5M | ||
| Q2 24 | $463.2M | $60.4M | ||
| Q1 24 | $450.4M | $74.1M |
| Q4 25 | $580.3M | $59.0M | ||
| Q3 25 | $557.9M | $51.1M | ||
| Q2 25 | $552.0M | $60.7M | ||
| Q1 25 | $544.6M | $67.9M | ||
| Q4 24 | $534.2M | $90.6M | ||
| Q3 24 | $521.4M | $99.0M | ||
| Q2 24 | $514.9M | $107.8M | ||
| Q1 24 | $510.0M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.0M | $18.4M |
| Free Cash FlowOCF − Capex | $15.7M | — |
| FCF MarginFCF / Revenue | 61.6% | — |
| Capex IntensityCapex / Revenue | 13.1% | — |
| Cash ConversionOCF / Net Profit | 2.32× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $28.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.0M | $18.4M | ||
| Q3 25 | $7.2M | $-8.7M | ||
| Q2 25 | $6.1M | $-7.5M | ||
| Q1 25 | $4.9M | $-7.5M | ||
| Q4 24 | $7.9M | $-24.0M | ||
| Q3 24 | $13.8M | $765.0K | ||
| Q2 24 | $3.5M | $-10.9M | ||
| Q1 24 | $10.8M | $-4.0M |
| Q4 25 | $15.7M | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $6.0M | — | ||
| Q3 24 | $9.1M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $9.9M | — |
| Q4 25 | 61.6% | — | ||
| Q3 25 | 17.8% | — | ||
| Q2 25 | 9.6% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 30.2% | — | ||
| Q2 24 | 5.4% | — | ||
| Q1 24 | 32.2% | — |
| Q4 25 | 13.1% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.2% | — | ||
| Q1 25 | 5.2% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 15.6% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 2.8% | — |
| Q4 25 | 2.32× | 1.50× | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.71× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LEGH
| Commercial Sales | $8.6M | 34% |
| Retail Store Sales | $6.0M | 24% |
| Inventory Finance Sales | $5.0M | 20% |
| Direct Sales | $4.4M | 17% |
| Other | $1.5M | 6% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
